Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs...
13 KB (1,060 words) - 05:46, 18 July 2024
squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. Cemiplimab (Libtayo) was developed by Regeneron Pharmaceuticals and first approved...
31 KB (3,266 words) - 05:29, 20 May 2024
$650 million from the development of REGN2810. REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best stock of...
26 KB (2,283 words) - 11:13, 25 August 2024
blood tests, lung and prostate cancer, marketed by Regeneron. Libtayo (Cemiplimab), for squamous cell skin cancer, marketed by Regeneron. Mozobil (Plerixafor)...
91 KB (8,778 words) - 06:05, 10 August 2024
include biologic immunotherapy agents ipilimumab, pembrolizumab, nivolumab, cemiplimab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor...
58 KB (6,430 words) - 23:50, 14 August 2024
prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab Libtayo mab human PD-1 Y cutaneous squamous cell carcinoma Cergutuzumab...
136 KB (4,020 words) - 07:14, 15 August 2024
non-small cell lung cancer, small cell lung cancer, biliary tract cancer Cemiplimab Libtayo Regeneron PD-1 2018 squamous cell carcinoma, basal cell carcinoma...
21 KB (2,093 words) - 18:53, 25 January 2024
keratitis Lanadelumab-flyo Takeda Pharmaceuticals hereditary angioedema Cemiplimab-rwlc Regeneron Pharmaceuticals cutaneous squamous cell carcinoma Amikacin...
34 KB (180 words) - 22:09, 8 April 2024
2018 – CCR4 Moxetumomab pasudotox – Lumoxiti – September 2018 – CD22 Cemiplimab – Libtayo – September 2018 – PD-1 Polatuzumab vedotin – Polivy – June...
57 KB (4,072 words) - 11:12, 5 August 2024
Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab† Lanadelumab...
39 KB (4,410 words) - 13:22, 25 August 2024